Emerging utility of once-weekly exenatide in patients with type 2 diabetes

Aditya Goud, Jixin Zhong, Sanjay RajagopalanDivision of Cardiovascular Medicine, Department of Medicine, University of Maryland, Baltimore, MD, USAAbstract: Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidenc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Goud A, Zhong J, Rajagopalan S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/90df0cef555e4836a09f0443ce732411
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:90df0cef555e4836a09f0443ce732411
record_format	dspace
spelling	oai:doaj.org-article:90df0cef555e4836a09f0443ce7324112021-12-02T06:25:56ZEmerging utility of once-weekly exenatide in patients with type 2 diabetes1178-7007https://doaj.org/article/90df0cef555e4836a09f0443ce7324112015-10-01T00:00:00Zhttps://www.dovepress.com/emerging-utility-of-once-weekly-exenatide-in-patients-with-type-2-diab-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Aditya Goud, Jixin Zhong, Sanjay RajagopalanDivision of Cardiovascular Medicine, Department of Medicine, University of Maryland, Baltimore, MD, USAAbstract: Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidence of both T2DM and CVD and coexistence of these disorders, numerous agents have been developed over the years to target complications. We focus on the efficacy and safety perspective of a long-acting formulation of the glucagon-like peptide-1 analog exenatide. Our review focuses on the various landmark trials, efficacy, safety profile, and patient perspectives of weekly exenatide that delineates its current and future role in the treatment of patients with T2DM and CVD.Keywords: incretin, glucagon-like peptide, hyperglycemia, glucose loweringGoud AZhong JRajagopalan SDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 505-512 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Goud A Zhong J Rajagopalan S Emerging utility of once-weekly exenatide in patients with type 2 diabetes
description	Aditya Goud, Jixin Zhong, Sanjay RajagopalanDivision of Cardiovascular Medicine, Department of Medicine, University of Maryland, Baltimore, MD, USAAbstract: Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidence of both T2DM and CVD and coexistence of these disorders, numerous agents have been developed over the years to target complications. We focus on the efficacy and safety perspective of a long-acting formulation of the glucagon-like peptide-1 analog exenatide. Our review focuses on the various landmark trials, efficacy, safety profile, and patient perspectives of weekly exenatide that delineates its current and future role in the treatment of patients with T2DM and CVD.Keywords: incretin, glucagon-like peptide, hyperglycemia, glucose lowering
format	article
author	Goud A Zhong J Rajagopalan S
author_facet	Goud A Zhong J Rajagopalan S
author_sort	Goud A
title	Emerging utility of once-weekly exenatide in patients with type 2 diabetes
title_short	Emerging utility of once-weekly exenatide in patients with type 2 diabetes
title_full	Emerging utility of once-weekly exenatide in patients with type 2 diabetes
title_fullStr	Emerging utility of once-weekly exenatide in patients with type 2 diabetes
title_full_unstemmed	Emerging utility of once-weekly exenatide in patients with type 2 diabetes
title_sort	emerging utility of once-weekly exenatide in patients with type 2 diabetes
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/90df0cef555e4836a09f0443ce732411
work_keys_str_mv	AT gouda emergingutilityofonceweeklyexenatideinpatientswithtype2diabetes AT zhongj emergingutilityofonceweeklyexenatideinpatientswithtype2diabetes AT rajagopalans emergingutilityofonceweeklyexenatideinpatientswithtype2diabetes
_version_	1718399949481181184

Emerging utility of once-weekly exenatide in patients with type 2 diabetes

Ejemplares similares